Abstract
Diamond-Blackfan anaemia (DBA) is a rare congenital red cell aplasia that presents in infancy. The exact molecular mechanism of ineffective erythropoiesis and red cell aplasia remains unclear, rendering targeted therapy elusive. The mainstay treatment of DBA is with regular blood transfusion and long-term corticosteroids, both of which have long-term side effects. We report a case of DBA successfully treated with danazol, a synthetic androgen, and suggest that danazol be considered as a viable option in patients who become refractory to steroids and are considered high risk or unfit for allogeneic stem cell transplantation.
Cite
CITATION STYLE
Chai, K. Y., Quijano, C. J., & Chiruka, S. (2019). Danazol: An Effective and Underutilised Treatment Option in Diamond-Blackfan Anaemia. Case Reports in Hematology, 2019, 1–5. https://doi.org/10.1155/2019/4684156
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.